Illustrative image – not actual.France's Vivalis is panning to buy austrian vaccine maker Intercell in European biotech industry.
The company is buying Intercell for $ 174 million (approx Rs 951 crore). Both companies are loss-making and the tie-up, billed as a merger of equals. The combined group - to be known as Valneva, with listings in Paris. The acquisition offers an opportunity to accelerate its drive to establish a profitable business based on finished products.
Source: Economic Times
